Merck has handed back rights to Anacor Pharmaceuticals' anti-fungal treatment, AN2690. Anacor inked an agreement with Schering-Plough in 2007 for rights to the treatment, and Merck acquired those rights after its buyout of Schering. Anacor says it will launch a late-stage trial of the drug while it looks for a new partner. Anacor release | Article